FibroBiologics, Inc.
FBLG
Positions held
Your positionsFBLG isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $7.72M | Enterprise value | $5.34M | Trailing P/E | — | Forward P/E | -0.34 |
| PEG | — | Price / book | 1.46 | Beta | 1.74 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -6.6% | ROA | -95.8% | Debt / equity | 0.32 |
| Current ratio | 2.64 | Free cash flow | -$8.37M | Analyst recommendation | none | Mean target | $12.50 |
| 52w high | $10.28 | 52w low | $0.62 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$4.1M | -$5.0M | -$3.2M | -$5.8M | -$4.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$4.0M | -$5.1M | -$2.6M | -$5.0M | -$4.5M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$18.6M | -$11.2M | -$16.5M | -$5.1M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$16.6M | -$13.7M | -$8.9M | -$4.5M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections
2026-09-29 · FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
2026-09-17 · FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
2026-09-03 · FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
2026-08-27 · FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
2026-08-27 · FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia
2026-08-26 · FibroBiologics Regains Compliance with Nasdaq Trading Rules
2026-08-24 · FibroBiologics Appoints Leigh Steinberg to Board of Directors
Price (daily)
Full chart · RSI · MACD · patterns